An open-label, multi-centre, extension study evaluating the long-term safety and tolerability of degarelix one-month depots in patients with prostate cancer. [EXTENSION OF 700040542]

Trial Profile

An open-label, multi-centre, extension study evaluating the long-term safety and tolerability of degarelix one-month depots in patients with prostate cancer. [EXTENSION OF 700040542]

Completed
Phase of Trial: Phase II/III

Latest Information Update: 12 Jun 2013

At a glance

  • Drugs Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Apr 2013 Planned number of patients changed from 130 to 137 as reported by German Clinical Trials Register.
    • 18 Dec 2009 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top